HRR as a Novel Biomarker in Sjögren's Syndrome
HRR as a Novel Plasma Inflammatory Biomarker in Sjögren's Syndrome: Findings From a Case-control Study
1 other identifier
observational
89
1 country
1
Brief Summary
Sjögren's syndrome (SS) is an autoimmune disorder characterized by chronic salivary and lacrimal gland dysfunction leading to dry mouth (xerostomia) and dry eye (xerophthalmia) sensation (1). Although dry mouth and dry eye are the main symptoms, the disease may influence many organs and systems. Diagnosis is made with ocular surface staining scores, anti-SS-A/SS-B auto-antibody positivity, and minor salivary gland biopsy (2). The Complete blood count (CBC) is a simple, inexpensive, accessible, and routinely used laboratory parameter that can be linked to oxidative stress, inflammation and microvascular flow resistance. Parameters include NLR and PLR values may be calculated by using CBC parameters (3). Neutrophil/lymphocyte ratio is used as an inflammatory marker in the diagnosis and prognosis of many cardiovascular diseases, malignancies, and infections (4-6). Peripheral inflammatory biomarkers of hematologic indices had been suggested by numerous studies to play a role during SS onset and progression.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Oct 2020
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 29, 2020
CompletedFirst Submitted
Initial submission to the registry
November 21, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 21, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
November 21, 2022
CompletedFirst Posted
Study publicly available on registry
December 1, 2022
CompletedDecember 2, 2022
November 1, 2022
2.1 years
November 21, 2022
November 30, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
HRR
hemoglobin-to-red cell distribution width ratio
change from baseline at 24 months
Study Arms (2)
89 SS patients
The medical records were analyzed retrospectively about the 89 patients with first onset of SS (SS group)
89 healthy control subjects
The medical records were analyzed retrospectively about the 89 age- and gender-matched individuals (Control group) who presented with normal control.
Interventions
All subjects went through a routine ocular examination, and the peripheral venous blood samples were collected and analyzed
Eligibility Criteria
A total of 89 SS patients and 89 age- and gender-matched healthy subjects were included. Eighty-nine primary SS patients who met the 2012 American College of Rheumatology (ACR-2012) classification criteria and 89 healthy controls were enrolled.
You may qualify if:
- must meet the 2012 American College of Rheumatology classification criteria,
- without systemic diseases, such as hypertension, diabetes, cardiovascular diseases, and chronic obstructive pulmonary disease,
- without malignant tumors,
- without renal failure,
- without liver diseases,
- without anemia,
- without smoking and alcohol consumption,
- without active infection,
- without other autoimmune diseases,
- without medicine usage that could influence the blood coagulation state,
- without a history of concurrent ocular diseases or trauma,
- without any surgery within three months.
You may not qualify if:
- systemic diseases, such as hypertension, diabetes, cardiovascular diseases, and chronic obstructive pulmonary disease,
- malignant tumor,
- renal failure,
- liver diseases,
- anemia,
- smoking and alcohol consumption,
- active infection,
- other autoimmune diseases,
- medicine usage that could influence the blood coagulation state,
- a history of concurrent ocular diseases or trauma,
- any surgery within three months.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Tianjin Eye Hospital
Tianjin, Tianjin Municipality, China
Related Publications (3)
Psianou K, Panagoulias I, Papanastasiou AD, de Lastic AL, Rodi M, Spantidea PI, Degn SE, Georgiou P, Mouzaki A. Clinical and immunological parameters of Sjogren's syndrome. Autoimmun Rev. 2018 Oct;17(10):1053-1064. doi: 10.1016/j.autrev.2018.05.005. Epub 2018 Aug 10.
PMID: 30103041RESULTYildiz F, Gokmen O. Haematologic indices and disease activity index in primary Sjogren's syndrome. Int J Clin Pract. 2021 Mar;75(3):e13992. doi: 10.1111/ijcp.13992. Epub 2021 Jan 19.
PMID: 33405348RESULTHu ZD, Sun Y, Guo J, Huang YL, Qin BD, Gao Q, Qin Q, Deng AM, Zhong RQ. Red blood cell distribution width and neutrophil/lymphocyte ratio are positively correlated with disease activity in primary Sjogren's syndrome. Clin Biochem. 2014 Dec;47(18):287-90. doi: 10.1016/j.clinbiochem.2014.08.022. Epub 2014 Sep 7.
PMID: 25204965RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Yan Wang
Tianjin Eye Hospital and Eye Institute, Nankai University Affiliated Eye Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 21, 2022
First Posted
December 1, 2022
Study Start
October 29, 2020
Primary Completion
November 21, 2022
Study Completion
November 21, 2022
Last Updated
December 2, 2022
Record last verified: 2022-11